table i.

Selected trials in the first-line or adjuvant setting

Reference (trial name)	Patients (n)	Arms	pfsa	p Value	osa	p Value
McGuire et al., 199611	410	Cyclophosphamide–cisplatin	13 months	<0.001	24 months	<0.001
		Paclitaxel–cisplatin	18 months		38 months
Trimbos et al., 200312 (icon1\action)	925	Surgery alone	65%	0.001	74%	0.08
		Platinum-based adjuvant	76% (5-year rfs)		82% (5-year os)
du Bois et al., 200413 (ago-gineco)	1282	Paclitaxel–epirubicin–carboplatin	18.4 months	ns	45.8 months	ns
		Paclitaxel–carboplatin	17.9 months		41.0 months
De Placido et al., 200414	273	Topotecan consolidation	18.2 months	ns	No values
		No consolidation	28.4 months
Katsumata et al., 200915	637	Dose-dense paclitaxel–carboplatin	28 months	0.0015	72%	0.03
		Standard paclitaxel–carboplatin	17.2 months		65% (3-year os)

^aMedian unless otherwise specified.

pfs = progression-free survival; os = overall survival; icon = International Collaborative Ovarian Neoplasm; action = Adjuvant Chemotherapy in Ovarian Neoplasm; rfs = relapse-free survival; ago = Arbeitsgemeinschaft Gynäkologische Onkologie; gineco = Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens; ns = nonsignificant.